Latest news with #ShareholdersFoundation
Associated Press
2 days ago
- Business
- Associated Press
Lawsuit Alert: Investors who lost money with Fortrea Holdings Inc. (NASDAQ: FTRE) should contact the Shareholders Foundation
SAN DIEGO, July 16, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Fortrea Holdings Inc. (NASDAQ: FTRE). Investors who purchased shares of Fortrea Holdings Inc. prior to July 2023 and continue to hold any of those NASDAQ: FTRE shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. On May 23, 2025, a NASDAQ: FTRE investor filed a lawsuit against Fortrea Holdings Inc. over alleged violations of securities laws. The plaintiff alleged that the defendants made false and/or misleading statements and/or failed to disclose that Fortrea overestimated the amount of revenue the Pre-Spin Projects were likely to contribute to the Company's 2025 earnings, that Fortrea overstated the cost savings it would likely achieve by exiting the TSAs, that as a result, the Company's previously announced EBITDA targets for 2025 were inflated, that accordingly, the viability of the Company's post-Spin-Off business model, as well as its business and/or financial prospects, were overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times. Those who purchased shares of Fortrea Holdings Inc. (NASDAQ: FTRE) should contact the Shareholders Foundation, Inc. CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon. View original content to download multimedia: SOURCE Shareholders Foundation, Inc.
Malaysian Reserve
2 days ago
- Business
- Malaysian Reserve
Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit
SAN DIEGO, July 16, 2025 /PRNewswire/ — Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Pacira BioSciences, Inc. (NASDAQ: PCRX) shares. Investors who purchased shares of Pacira BioSciences, Inc. prior to August 2023 and continue to hold any of those NASDAQ: PCRX shares also have certain options and contact the Shareholders Foundation at mail@ or call +1(858) 779 – 1554. On January 13, 2025, an investor in NASDAQ: PCRX shares filed a lawsuit over alleged violations of securities laws by Pacira BioSciences, Inc. The plaintiff alleged that the defendants made false and/or misleading statements and/or failed to disclose that defendants created the false impression that Pacira had sufficient patent protections on Exparel, and as such, the ability to expand the marketing, production, and sales of Exparel, which Pacira stated was critical to its future growth and revenue, that Pacira knew that the '495 patent was not as protective as Pacira publicly touted because on June 6, 2023, the United States District Court for the District of New Jersey issued a ruling in eVenus Pharmaceutical Laboratories, Inc.'s favor regarding claims construction in another case filed by Pacira in a failed attempt to protect Exparel, and that therefore, when the '495 patent was invalidated in another case Pacira filed against eVenus, investors and analysts alike were shocked by the concerning news that Exparel, which accounts for approximately 80% of Pacira's revenue, did not have sufficient patent protection to prevent another company from producing a generic during the life of the patent. Those who purchased NASDAQ: PCRX shares should contact the Shareholders Foundation, Inc. CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 mail@ 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
Associated Press
30-04-2025
- Business
- Associated Press
Lawsuit for Investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced by the Shareholders Foundation
SAN DIEGO, April 30, 2025 /PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Investors who purchased shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) prior to October 2022 and continue to hold any of those NYSE: ATNM shares also have certain options and contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. On March 27, 2025, a NYSE: ATNM investor filed a lawsuit against Actinium Pharmaceuticals, Inc. over alleged violations of securities laws. The plaintiff alleged that the Defendants failed to disclose that the Company's data from the Sierra Trial was unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA, that the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate Sierra's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA, that as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved, and that as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Those who purchased shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) should contact the Shareholders Foundation, Inc. CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon. View original content to download multimedia: SOURCE Shareholders Foundation, Inc.
Business Wire
22-04-2025
- Business
- Business Wire
Lawsuit for Investors in shares of Venture Global, Inc. (NYSE: VG) announced by the Shareholders Foundation
SAN DIEGO--(BUSINESS WIRE)--The Shareholders Foundation, Inc. announced that a lawsuit was filed on February 17, 2025 for certain investors in shares of Venture Global, Inc. (NYSE: VG) in the U.S. District Court for the Southern District of New York (Docket number: 25-CV-01364). A lawsuit was filed for certain investors in shares of Venture Global, Inc. (NYSE: VG). Investors in Venture Global, Inc. (NYSE: VG) should contact the Shareholders Foundation. Share Investors who purchased shares of Venture Global, Inc. (NYSE: VG) have certain options and should contact the Shareholders Foundation at mail@ or call +1(858) 779 - 1554. On February 17, 2025, an investor in NYSE: VG shares filed a lawsuit against Venture Global, Inc over alleged securities laws violations. The plaintiff alleges on behalf of purchasers of Venture Global, Inc. (NYSE: VG) common shares who purchased NYSE: VG shares pursuant and/or traceable to Venture's registration statement for the initial public offering held on or about January 24, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that the IPO's offering documents were materially false and/or misleading and/or failed to disclose information concerning Venture Global's repeated confidence in Venture Global's ability to utilize its approach to deliver liquefied natural gas ('LNG') to the world. Those who purchased Venture Global, Inc. (NYSE: VG) shares should contact the Shareholders Foundation, Inc. The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
